Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

NF Featured in the NCI Annual Plan

By October 3, 2017December 18th, 2023Awareness, NF1, Science & Research, Story of NF

Each year, the National Cancer Institute (NCI) prepares a report to communicate to the President and to Congress NCI’s research priorities, progress made to date, scientific areas of opportunity that will advance cancer research and improve patients’ lives, and the funding needed to do so.

This year, in addition to highlighting scientific opportunities, the FY2019 report included stories to highlight how investments in cancer research help people living longer and healthier lives. One of these stories is a profile of NF Hero Philip Moss, relaying his NF journey since April 2015, when he first joined the Phase II MEK inhibitor clinical trial.

Philip remains in the trial, and the tumor on his neck has shrunk by half. In this video  from December 2016, Philip gave an update on the incredible progress.

Read more about Philip’s journey in the NCI Annual Plan here.

Close Menu